Eisai Says Aricept Patent Claim Upheld by Japan Supreme Court

Eisai Co., maker of the Alzheimer’s disease drug Aricept, said Japan’s Supreme Court ruled in its favor to extend a patent for the world’s best-selling treatment for the condition.

Eisai’s patent is valid until June 22, 2013, after the court rejected an appeal by generic drugmakers, according to a faxed statement from the Japanese company today.

To contact the reporter on this story: Go Onomitsu in Tokyo at gonomitsu@bloomberg.net

To contact the editor responsible for this story: Kyung Bok Cho at kcho7@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.